Professor Christopher Parish of the John Curtin School of Medical Research at The Australian National University gives this public lecture discussing emerging cancer therapies. This Public Lecture was held in conjunction with The Bootes Course on Translational Medicine.
Professor Parish is head of The Cancer and Vascular Biology Group which has been working for a number of years on the molecular basis of cell adhesion, cell migration and cell invasion, with a particular emphasis on the immune system, tumour metastasis and the growth of new blood vessels (angiogenesis).
Of particular interest has been the role of anionic carbohydrates, such as heparan sulfate, in these processes and the enzyme, heparanase, that degrades heparan sulfate. More recent studies have led to mechanisms of epigenetic control of immune response genes.
In addition the Group aims to apply its basic research findings in cancer and immunology to (i) develop new drugs, notably heparan sulfate mimetics, which inhibit inflammation, cancer spread and angiogenesis and (ii) design clever vaccines for cancer immunotherapy.
No comments:
Post a Comment